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Uterine Sarcomas
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1  Epidemiology
The term sarcoma comes from a Greek word 
meaning “fleshy growth”.
Gynaecological sarcomas are uncommon 
tumours with aggressive behaviour that 
account for approximately 1% of all female 
genital tract malignancies and 3–7% of  uterine 
cancers (D’Angelo and Prat 2010; Major et al. 
1993). Although rare, the most frequent of all 
gynaecological sarcomas is leiomyosarcoma.
The great majority of sarcomas arise in the 
uterus and are classified according to the histo-
logic tissue from which they are derived, either 
smooth muscle or endometrial stroma. Although 
uncommon, the histopathological diversity of 
gynaecological sarcomas have contributed to 
many inaccuracies and lack of consensus in 
nomenclature in the past.
Sarcomas can also develop at other sites in the 
female genital tract with different features, for 
example, ovarian fibrosarcoma, vulvovaginal 
leiomyosarcoma or rhabdomyosarcoma; how-
ever these tumours are extremely rare and are 
outside the scope of this chapter.
2  Pathology
The current World Health Organization (WHO) 
classification of tumours of the female reproduc-
tive organs (Kurman et al. 2014), recently revised 
and published in 2014, classifies mesenchymal 
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tumours of the uterine corpus into smooth muscle 
origin, endometrial stromal origin, mixed epithelial- 
mesenchymal origin and miscellaneous tumours.
In comparison with the previous WHO 2003 
classification, the new classification reintroduces 
high- grade endometrial stromal sarcoma as a 
separate entity, supported by emerging recent 
molecular and morphological data, and replaces 
the designation “undifferentiated endometrial 
sarcoma” by undifferentiated uterine sarcoma to 
reflect the fact that an endometrial origin is not 
certain (McCluggage et al. 2014).
Uterine sarcomas more frequently exhibit 
early peritoneal and haematogenous spread with 
distant metastases, instead of starting to spread 
locally in the pelvis and to lymph nodes as carci-
nomas do (Seddon and Davda 2011).
2.1  Smooth Muscle Tumours
Smooth muscle tumours are composed of cells 
showing smooth muscle differentiation arising 
within the myometrium that can be either benign 
or malignant. Because they arise in the stroma, 
the classic histological criteria for invasion are 
not so easy to define as in epithelial tumours.
This designation comprises:
• Classic benign leiomyoma (i.e., the most fre-
quent uterine tumour)
• Smooth muscle tumour of uncertain malig-
nant potential (STUMP), also called atypical 
smooth muscle neoplasm, a lesion not fulfill-
ing entirely the criteria for a leiomyoma or 
leiomyosarcoma
• Leiomyosarcoma, a malignant tumour that occa-
sionally shows epithelioid or myxoid features
Leiomyosarcomas and leiomyomas are inde-
pendent entities with differing cytogenetic abnor-
malities that can however coexist (McCluggage 
et al. 2014; Bodner et al. 2003). Classical  teaching 
books state that malignant transformation should 
be suspected in rapid growth of a leiomyoma in a 
menopausal woman; however the most recent 
evidence supports that uterine sarcomas do not 
generally arise from pre-existing leiomyomas, 
with only very rare exceptions (about 0.2% of 
cases). By consensus from genetic studies, the 
current concept is that most sarcomas arise inde-
pendently (Hodge and Morton 2007; McCluggage 
2002a). Furthermore, rapid growth can also occur 
in premenopausal women in leiomyoma.
2.2  Endometrial Stromal Tumours
Endometrial stromal neoplasms are a subset of 
uterine mesenchymal neoplasms that account for 
less than 10% of all uterine sarcomas (Chan et al. 
2008). These rare uterine neoplasms mimic pro-
liferative endometrium; however, they have myo-
metrial and/or vascular invasion (Kurman et al. 
2014).
Recent molecular genetics and immunohisto-
chemistry advances have improved the under-
standing of these lesions and helped to redefine 
the WHO classification into more meaningful 
categories with distinct prognosis (Kurman et al. 
2014; Ali and Rouzbahman 2015; Conklin and 
Longacre 2014; Xue and Cheung 2011), namely
• Low-grade endometrial stromal sarcoma
• High-grade endometrial stromal sarcoma
• Undifferentiated uterine sarcoma
In tumours in which a focal smooth muscle 
differentiation coexists, the neoplasm is consid-
ered an endometrial stromal sarcoma if the 
smooth muscle component involves <30% of the 
total lesion  volume. Tumours composed of a 
larger smooth muscle component are designated 
as “mixed endometrial stromal and smooth mus-
cle neoplasms” or stromomyomas. However, 
there is still few data regarding these lesions 
(Kurman et al. 2014).
2.3  Mixed Epithelial 
and Mesenchymal Tumours
This category includes adenosarcoma, a rare 
tumour that accounts for 5–9% of uterine 
 sarcomas. In this lesion the epithelial component 
is benign or atypical, and the stromal component 
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is low-grade malignant (Tse et al. 2011). It is a 
difficult diagnosis to make requiring an experi-
enced gynaecological pathologist (Blom and 
Guerrieri 1999).
Even though adenosarcomas typically have a 
low malignant potential, there is however a 
 subgroup defined as having sarcomatous over-
growth, with pure sarcoma occupying at least 
25% of the tumour (McCluggage et al. 2014).
Carcinosarcoma, previously called malignant 
Müllerian tumour, has recently been reclassified 
as a dedifferentiated or metaplastic form of 
 endometrial carcinoma (type II cancer). In addi-
tion, the epidemiology, risk factors, and clinical 
behaviour associated with carcinosarcoma 
 suggest a closer relationship to endometrial car-
cinoma than to other sarcomas (McCluggage 
2002a, b).
2.4  Miscellaneous Mesenchymal 
Tumours
This group includes rhabdomyosarcoma, which 
is a notably rare tumour that shows skeletal mus-
cle differentiation, occurring both in the vagina 
and uterine corpus and cervix, typically arising in 
children and adolescents.
For this chapter only, malignant uterine sarco-
mas with mesenchymal and mixed epithelial- 
mesenchymal origin will be considered as 
summarized in Table 1.
3  Clinical Background
The clinical presentation of uterine sarcomas is 
non-specific, with a peak incidence between 50 
and 65 years of age. Of note, low-grade endome-
trial stromal sarcomas occur mainly in premeno-
pausal women (D’Angelo and Prat 2010; Conklin 
and Longacre 2014).
Frequently there is history of a rapidly grow-
ing uterine mass, abnormal vaginal bleeding and 
pelvic or abdominal pain.
Less frequently, leiomyosarcoma can present 
hemoperitoneum (due to tumour rupture), or 
symptoms resulting from extrauterine extension 
or metastases (D’Angelo and Prat 2010).
The diagnosis of uterine sarcomas is fre-
quently unexpected, discovered incidentally on 
histopathology analysis following hysterectomy, 
often for benign diseases. Of those patients 
undergoing hysterectomy for a preoperative diag-
nosis of leiomyoma, 0.5% is subsequently diag-
nosed with leiomyosarcoma (Wu et al. 2011).
African-american women have an approxi-
mately twofold higher incidence of leiomyosarco-
mas (but not other types of uterine sarcoma) than 
caucasian women (Sherman and Devesa 2003).
Occasional cases are associated with long- term 
tamoxifen therapy, polycystic ovarian disease, pro-
longed estrogenic stimulation or pelvic irradiation. 
There are also some associated hereditary condi-
tions such as hereditary leiomyomatosis/renal cell 
carcinoma syndrome and survivors of childhood 
retinoblastoma (Toro et al. 2003; Yu et al. 2009).
Obesity, diabetes and younger age at  menarche 
have been associated with increased risk of endo-
metrial stromal sarcomas, although the molecular 
mechanisms involved are yet to be elucidated 
(Felix et al. 2013).
Compared with the more common endome-
trial carcinomas (epithelial neoplasms), uterine 
sarcomas behave aggressively and are associated 
with a poorer prognosis.
4  Staging
Staging is surgical, including total hysterectomy 
with bilateral salpingo-oophorectomy, and 
remains the most powerful prognostic factor for 
Table 1 Malignant uterine sarcomas
Mesenchymal origin
Mixed epithelial and 
mesenchymal origin
Smooth muscle origin Adenosarcoma
 Leiomyosarcoma
Endometrial stroma and 
related origin
  Low-grade endometrial 
stromal sarcoma
  High-grade endometrial 
stromal sarcoma
  Undifferentiated uterine 
sarcoma
Uterine Sarcomas
uterine sarcomas. However in pretreatment 
 evaluation, staging largely depends on imaging 
as the clinical evaluation is very limited.
Due to their different biologic behaviour, in 
2009 FIGO introduced two new dedicated stag-
ing systems, specifically designed for uterine sar-
comas, in which the morphological tumour 
subtype determines which staging system is used: 
one staging system for leiomyosarcoma and 
endometrial stromal sarcoma and a different sys-
tem for adenosarcoma (Prat 2009a, b) (Table 2).
Adenosarcoma tends to arise at the endome-
trial or cervical surface, progressively invading 
the myometrium or cervical stroma in a similar 
way to endometrial carcinomas. The staging sys-
tem is comparable to endometrial carcinomas, 
whereas leiomyosarcoma and endometrial  stromal 
sarcoma that usually arise within the myometrium 
and have a different tumoural progression are 
staged in a different fashion.
5  Imaging
Imaging plays an important role in the evaluation 
of disease extent and treatment decision, even 
though the diagnosis relies on the histological 
examination. Endometrial sampling may yield 
the correct diagnosis but not in all patients: cases 
that arise within the endometrium may be indis-
tinguishable from endometrial carcinoma, 
whereas those that arise from the myometrium 
may be indistinguishable from degenerating leio-
myomas (Sala et al. 2013).
Table 2 2009 FIGO staging systems for uterine sarcomas
Uterine leiomyosarcoma and endometrial stromal sarcoma
Stage I Tumour limited to uterus
IA ≤5 cm
IB >5 cm
Stage II Tumour extends beyond the uterus, within the pelvis
IIA Adnexal involvement
IIB Involvement of other pelvic tissues
Stage III Tumour invades abdominal tissues (not just protruding into the abdomen)
IIIA One site
IIIB More than one site
IIIC Metastasis to pelvic and/or para-aortic lymph nodes
Stage IV
IVA Tumour invades bladder and/or rectum
IVB Distant metastasis
Uterine adenosarcoma
Stage I Tumour limited to uterus
IA Tumour limited to endometrium/endocervix with no myometrial invasion
IB Less than or equal to half myometrial invasion
IC More than half myometrial invasion
Stage II Tumour extends beyond the uterus, within the pelvis
IIA Adnexal involvement
IIB Involvement of other pelvic tissues
Stage III Tumour invades abdominal tissues (not just protruding into the abdomen)
IIIA One site
IIIB More than one site
IIIC Metastasis to pelvic and/or para-aortic lymph nodes
Stage IV
IVA Tumour invades bladder and/or rectum
IVB Distant metastasis
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Pre-surgical subtyping of uterine sarcomas is 
very important for therapeutic management. 
Even though the imaging findings of uterine sar-
comas have a considerable overlap, there are 
however some specific features that can narrow 
the differential diagnosis list.
Ultrasound is usually the first-line study to 
evaluate women for potential uterine pathology 
as it is a readily available, non-invasive and rela-
tively inexpensive technique. It gives an initial 
evaluation of the size and location of the lesion 
and may identify features suggestive of aggres-
siveness; however, the accuracy is very low.
Computed tomography (CT) is mainly used 
for staging in the assessment of extra-pelvic dis-
ease, distant metastases and follow-up.
The primary modality for imaging uterine sar-
comas is magnetic resonance imaging (MRI) due 
to the improved ability of this technique to delin-
eate local disease.
When evaluating a possible sarcomatous uter-
ine lesion with MRI, there are some specific key 
points that are important to evaluate as described 
in Table 3 (McCluggage et al. 2014).
5.1  Leiomyosarcoma
Leiomyosarcomas are rare typically large lesions 
(>10 cm) presenting as solitary masses with areas 
of haemorrhage and necrosis that may bulge into 
and distort the uterine cavity, but the epicentre is 
in the myometrium (Kurman et al. 2014).
Pelvic ultrasound is commonly the first-line 
study to evaluate women for potential uterine 
pathology. Some findings such as heterogeneous 
echo texture, central necrosis and colour Doppler 
findings of irregular vessel distribution might 
suggest the diagnosis of leiomyosarcoma; 
 however sonographic evaluation is highly unspe-
cific and hard to differentiate from leiomyomas 
(the most common myometrial tumour) (Amant 
et al. 2009).
Leiomyosarcomas commonly cause massive 
uterine enlargement, demonstrating heteroge-
neous low to intermediate signal intensity and 
scattered hyperintense foci on T1-weighted 
images (WI), whereas on T2-WI they are irregu-
lar and ill-defined lesions with intermediate to 
high signal intensity with cystic areas denoting 
necrosis (present in >50% of cases) (Santos and 
Cunha 2015). Detection of scattered foci of 
haemorrhages or necrosis may suggest the diag-
nosis; however signal intensity alone is not a reli-
able indicator of malignancy (Amant et al. 2009) 
(Fig. 1).
As stated before, leiomyosarcomas and leio-
myomas are independent entities with differing 
cytogenetic abnormalities that can however coex-
ist (Bodner et al. 2003; Hodge and Morton 2007; 
Table 3 Key points in the evaluation of sarcomatous uterine lesions
Tumour limits/interface Early-stage uterine leiomyosarcomas can be well-circumscribed, while more advanced 
lesions typically have an irregular contour. On the other hand, endometrial stromal 
sarcomas may exhibit a diffusely infiltrative pattern of myometrial invasion
Depth of myometrial 
invasion
Important in the substaging of stage I adenosarcomas: Stage IA tumours are limited to 
the endometrium, stage IB invades less than or half of myometrium thickness and stage 
IC equates to more than one half myometrial invasion. It is also considered a risk factor 
for recurrence
Since most other uterine sarcomas are predominantly myometrial-based lesions, 
myometrial invasion is not considered in the staging of these neoplasms
Cervical involvement It has an adverse influence on prognosis, for example, in the case of a leiomyosarcomas
Adnexal involvement Adnexal involvement affects the tumour stage (FIGO stage IIA) and may occur as  
result of direct extension or metastatic spread of tumour
Lymph nodes Pelvic or para-aortic lymph node involvement upstages uterine sarcomas to stage IIIC
Involvement of pelvic 
tissues
Other sites of pelvic tumour involvement should be documented since this equates to 
FIGO stage IIB
Involvement of omentum 
and other abdominal 
tissues
The number of affected locations in peritoneal tissue is important as FIGO stage IIIA 
equates to one site of abdominal involvement and IIIB to more than one site
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McCluggage 2002a). Benign leiomyomas 
develop primarily in women of reproductive age 
and typically stabilize or diminish in size follow-
ing menopause. In contrast, increasing age is a 
significant risk factor for uterine sarcomas, and 
new or a rapidly growing uterine mass warrants 
further evaluation in menopausal women.
There is however a considerable overlap in 
the MR appearance, signal intensity and 
enhancement characteristics of leiomyosarcoma 
and leiomyomas with atypical imaging features 
(Schwartz et al. 1998; Cornfield et al. 2010). As 
so the diagnosis of uterine sarcomas can be 
 incidental in histopathology analysis following 
hysterectomy (Sagae et al. 2004). It should also 
be highlighted that with the development of 
 laparoscopic surgery, morcellation of presumed 
leiomyomas has resulted in suboptimal treat-
ment in patients with previously undiagnosed 
uterine sarcomas and reinforcing the need of 
better preoperative tumour characterization 
(Sutton 2013).
It has been suggested that an irregular contour, 
high signal on T2-WI and hyperintense areas on 
T1-WI could favour leiomyosarcoma against 
leiomyoma, but the specificity of this finding has 
not been established (Cornfield et al. 2010; 
Murase et al. 1999; Tanaka et al. 2004). The 
absence of calcifications is also a consistent find-
ing in leiomyosarcomas (Schwartz et al. 1998).
a b
c d
Fig. 1 Leiomyosarcoma in a 56-year-old woman. 
Coronal (a) and sagittal (b) T2-WI show marked uterine 
enlargement due to a heterogeneous myometrial tumour 
that invades the pelvic wall on the left (arrow), with 
intense enhancement in solid areas showed here in axial 
(c) and coronal (d) gadolinium-enhanced T1-WI with fat 
suppression and extensive areas of tumoural necrosis
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The myxoid and epithelioid variants can have 
a more diverse appearance, and the establishment 
of the diagnosis is particularly difficult in these 
cases (Figs. 2 and 3).
Leiomyosarcomas demonstrate early hae-
matogenous spread to the lungs and liver (Sala et 
al. 2013). Involvement of pelvic lymph nodes is 
uncommon and usually associated with advanced 
intra-abdominal disease and decreased survival 
(Leitao et al. 2003; Kapp et al. 2008) (Fig. 4).
The major advantage of diffusion-weighted 
 imaging (DWI) sequences is the delineation of 
malignant lesions DWI seems to be a potentially use-
ful tool in soft tissue  characterization of large uterine 
lesions: the high nuclear-to-cytoplasm ratio in tumour 
cells limits intracellular motion of water molecules in 
uterine sarcomas and these lesions are depicted as 
hyperintense lesions on DWI and low signal on the 
corresponding apparent diffusion coefficient (ADC) 
maps.
a b c
d e
Fig. 2 Myxoid leiomyosarcoma in a 60-year-old, appear-
ing to grow from a solid anterior myometrial nodule 
(asterisk on sagittal – a and axial T2-WI – b) and 
 communicating with an exuberant multiloculated cystic 
component, with multiple fluid levels (c). On axial T1-WI 
with fat saturation and contrast administration (d and e), 
some levels have high signal (arrow) related to haemor-
rhagic content
a b c
Fig. 3 Epithelioid leiomyosarcoma in a 43-year-old 
woman. This subserosal tumour arises from the right pos-
terior uterine wall. On sagittal T2-WI (a and b) the flow 
voids of the connecting vessels are easily seen (arrows). 
On axial T2-WI (c) this lesion is seen on the right of the 
uterine cervix. The endometrial cavity is indistinct
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Leiomyosarcomas display restriction in DWI 
studies.
DWI proved to reduce misdiagnoses of uterine 
sarcoma as benign leiomyoma with high accu-
racy (Thomassin-Naggara et al. 2013). DWI 
combined with T2-WI is even better than DWI 
alone in the differentiation of uterine sarcomas 
from benign leiomyomas (Namimoto et al. 2009). 
It is however important to recall, as a potential 
pitfall, that non-malignant lesions with high cel-
lular density, such as high celular leiomyomas, 
may have restricted diffusion.
Positron emission tomography (PET) com-
bined with CT adds metabolic information to 
morphologic data; However the main role of 
PET-CT is confined to post-therapy surveillance 
in order to detect distant metastasis or local recur-
rence, it appears to exist a significant variability 
in fluorodeoxyglucose (FDG) mean standard 
uptake values (SUVs) between benign and malig-
nant neoplasms (Tirumani et al. 2013; Kao et al. 
2011).
5.2  Endometrial Stromal 
Sarcomas
The ultrasonographic evaluation of these lesions is 
highly unspecific. They appear as heterogeneous 
hypoechoic endometrial masses with irregular 
endometrial-myometrial interface, sometimes 
with fingerlike invasive myometrial projections 
and low-resistance intralesional arteries on 
Doppler (Amant et al. 2009; Gandolfo et al. 2000).
T2-WI are the most helpful MR sequences in 
detecting the endometrial nature of the tumours 
and its relationships with surrounding myome-
trium (Gandolfo et al. 2000).
Another feature that may suggest endometrial 
stromal sarcoma, observed in about one third of 
the cases, is the continuous extension of the 
lesion into adjacent structures most commonly 
the ovary, but also the fallopian tubes, the sur-
rounding ligaments and vessels (Koyama et al. 
1999). Digitiform tumour extension is best delin-
eated on DWI (Tamai et al. 2008), differing from 
a b c
d e f
Fig. 4 Leiomyosarcoma in a 55-year-old woman. Coronal 
T2-WI of the pelvis (a) shows marked uterine enlargement 
due to a heterogeneous myometrial tumour with areas of 
high signal. Axial T2-WI, at the level of the pulmonary 
bases (b and c), reveals pulmonary metastases and 
 posterior mediastinum enlarged lymph nodes (c). In axial 
gadolinium-enhanced T1-WI with fat suppression (d), the 
tumour demonstrates early intense peripheral enhance-
ment with irregular central zones of low signal intensity 
denoting extensive necrosis. Endometrial cavity is difficult 
to depict. DWI-MR (e) and ADC map (f) show restricted 
diffusion in the solid areas of the lesion
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intravenous leiomyomatosis due to tumoural 
high signal (Riopel et al. 2005).
Lymph node metastases occur in up to 30% of 
patients, and besides pelvic chain, spread to para-
aortic nodes has also been reported (Fekete and 
Vellios 1984).
5.2.1  Low-Grade Endometrial 
Stromal Sarcoma
These tumours occur in a younger age group 
compared to high-grade lesions, usually involve 
the endometrium forming a polyp of homoge-
neous high signal intensity on T2-WI, which may 
be infarcted or haemorrhagic (Fig. 5).
There is myometrial invasion and an infiltra-
tive growth pattern that may form deceptively 
well-demarcated nodules in the myometrium or 
may cause myometrial diffuse thickening without 
evidence of a well-defined tumour (Tamai et al. 
2008). In some cases this diffuse thickening can 
be been misinterpreted as adenomyosis and, if 
more localized, can present as a myometrial mass 
mimicking a degenerated cystic leiomyoma, how-
ever without the typical well-defined border. In 
the presence of a large myometrial lesion, it is 
extremely important to evaluate the adjacent 
endometrial thickness, endometrial-myometrial 
border and lesion margin (Koyama et al. 1999).
On MRI, these lesions have heterogeneous 
signal intensity on both T1- and T2-WI (Gandolfo 
et al. 2000; Koyama et al. 1999), and the most 
important imaging feature is the presence of 
bands of low signal intensity on T2-WI invading 
the myometrium, representing preserved muscu-
lar bundles.
Tumour enhancement is commonly heteroge-
neous and iso- or hyperintense when compared 
with normal myometrium (in contrast to endome-
trial carcinoma, which enhances less than normal 
myometrium) (Sala et al. 2013). Sometimes signal 
voids can be observed reflecting the hypervascular 
nature of these tumours (Koyama et al. 1999).
Although low-grade endometrial stromal sar-
comas have an indolent clinical course there is a 
significant tendency for recurrence (Fig. 6).
5.2.2  High-Grade Endometrial 
Stromal Sarcoma
Recently a subset of endometrial stromal sarco-
mas has been discovered with a unique gene rear-
rangement, distinct morphologic features and an 
intermediate prognosis between low-grade and 
undifferentiated stromal sarcomas, supporting 
the need to consider these tumours a separated 
category (Lee et al. 2012).
On MRI, the T2-WI hypointense preserved 
bundles of myometrial fibres are much thinner, 
scattered and harder to depict compared to low-
grade lesions, due to a more aggressive growth 
(Koyama et al. 1999) (Fig. 7).
a b c
Fig. 5 Low-grade endometrial stromal sarcoma in a 
62-year-old woman with postmenopausal bleeding. 
Sagittal (a) and axial (b) T2-WI of the pelvis demonstrate 
a high signal endometrial polypoid lesion, with ill-defined 
endometrial/myometrial border and without evidence of a 
well-defined myometrial mass. DWI-MRI (c) allowed 
better identification of the lesion and revealed bands of 
low signal intensity (arrow) representing preserved bun-
dles of the myometrium. Histopathology revealed internal 
myometrial invasion
Uterine Sarcomas
a b
c d
Fig. 6 Low-grade endometrial stromal sarcoma recur-
rence in a 70-year-old woman 2 years after surgery. Axial 
(a) and sagittal (b) T2-WI images demonstrate a large het-
erogeneous cystic and solid mass in the vaginal cuff. On 
axial T1-WI (c) the lesion in hypointense, with faint 
enhancement after contrast on T1-WI fat supressed acqui-
sition (d).
a b c
d e f
Fig. 7 High-grade endometrial stromal sarcoma in a 
75-year-old woman. Coronal (a) and sagittal T2-WI (b) 
revealed a heterogeneous mass with necrotic areas (aster-
isk) extending to the cervix, with heterogeneous enhance-
ment after gadolinium administration (c), high-signal foci 
on T1-WI (d) (arrow) denoting haemorrhage, and marked 
restriction on DWI (e) and ADC map (f). The gross exam-
ination of the specimen revealed a heterogeneous endo-
metrial mass invading the myometrium and reaching the 
cervix denoting aggressive growth
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The tumoural extension to adjacent organs, 
supporting structures and vascular elements is 
also characteristic (Fig. 8).
5.2.3  Undifferentiated Uterine 
Sarcoma
This is a tumour arising in the endometrium or 
the myometrium, lacking any resemblance to 
proliferative-phase endometrial stroma.
There are few studies describing the charac-
teristic appearance of undifferentiated uterine 
sarcoma, suggesting that they appear similarly to 
high-grade endometrial stromal sarcomas and as 
so presenting as polypoid masses that frequently 
fill the endometrial cavity, with irregular mar-
gins, multiple marginal tumour nodules,  extensive 
areas of haemorrhage, necrosis and myometrial 
invasion (Tirumani et al. 2013) (Fig. 9).
These tumours are typically characterized by 
a haphazard arrangement of variably sized blood 
vessels, as so manifesting as enhancing masses 
that can have marked vascular and lymphatic 
invasion (Amant et al. 2009; Santos and Cunha 
2015) (Fig. 10).
Also metastatic extrauterine disease is more fre-
quent than in the previously described types of 
endometrial stromal sarcoma (Tanner et al. 2012).
5.3  Adenosarcoma
The majority of adenosarcomas are present in the 
endometrium, but they may also arise from the 
myometrium, cervix or extrauterine Müllerian 
tissues (Huang et al. 2014).
Sonographic features of adenosarcoma may 
include expansion of endometrial cavity associ-
ated with a thickened heterogeneous and cystic 
complex mass. These features can mimic gesta-
tional trophoblastic disease (Santos and Cunha 
2015; Chourmouzi et al. 2003).
These neoplasms present as polypoid solid, 
well-circumscribed multiseptated cystic mass 
with heterogeneous solid components. They 
usually arise from the fundus, sometimes pro-
trude through the cervical os, and typically 
cause marked enlargement of the uterus with a 
thin myometrium (Amant et al. 2009; Santos 
and Cunha 2015; Chourmouzi et al. 2003) (Fig. 
11). On MR the cysts have hight signal on 
T2-WI, representing glandular epithelial com-
ponents or necrosis, solid component shows 
T2-WI hypointensity, resulting in a  latticework 
appearance due to the intervening septa that 
enhance after contrast (Chourmouzi et al. 2003; 
Szklaruk et al. 2003) (Fig. 12).
a b
Fig. 8 High-grade endometrial stromal sarcoma in a 
64-year-old woman. Axial (a) and sagittal (b) T2-WI 
show a heterogeneous multinodular tumour with exten-
sive myometrial invasion and high-signal tumoural exten-
sion along pelvic vessels (black arrow)
Uterine Sarcomas
a b c
d e f
Fig. 9 Undifferentiated uterine sarcoma in a 56-year-old 
woman. Axial (a), coronal (b) and sagittal (c) T2-WI show 
marked uterine enlargement due to a large subserosal het-
erogeneous tumour, with lobulated contours, showing 
extensive cystic and necrotic areas (arrows). On 
T1-weighted image (d) haemorrhage can be appreciated 
(arrow-head). The tumour shows marked restriction on 
DWI (e) and on the ADC map (f)
a b c
d e
f
Fig. 10 Undifferentiated uterine sarcoma in a 72-year- 
old woman. Sagittal (a), coronal (b) and axial and (c) 
T2-WI show a polypoid mass with heterogeneous high 
signal intensity within the endometrial cavity, protruding 
through the cervical os into the vagina. On T1-WI FS after 
gadolinium administration, in the same three planes (d–f) 
the lesion enhances heterogeneously compared to the 
peripheral myometrium
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a b
Fig. 11 Adenosarcoma in a 48-year-old woman present-
ing with pelvic mass and vaginal discharge. Sagittal (a) 
and axial (b) T2-WI demonstrate a large, heterogeneous, 
high-signal intensity mass centred in the endometrial cav-
ity, protruding trough the cervical canal and prolapsing
a b c
d e f
Fig. 12 Adenosarcoma in a 77-year-old woman present-
ing with post-menopausal bleeding. Sagittal (a), axial (b) 
and axial of the uterine body (c) T2-WI of the pelvis dem-
onstrate a huge endometrial mass with cystic spaces and 
heterogeneous solid components. The uterine contour is 
preserved. Axial DWI-MR (d) reveals high signal inten-
sity and low signal on the ADC map (e). T1-WI fat sup-
pressed after administration of contrast (f) shows early 
enhancement of the septa and solid areas. No myometrial 
invasion was present on pathology
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The cases of adenosarcoma with sarcomatous 
overgrowth are described in the literature as large 
pelvic masses with heterogeneous signal inten-
sity, cystic areas and transperitoneal extension 
with contiguous intravascular growth (Kim et al. 
2011).
6  Prognosis and Treatment
Overall 5-year survival for uterine sarcomas 
ranges between around 18–55%, considerably 
lower than for endometrial carcinomas 
(Koivisto-Korander et al. 2008). Prognostic fac-
tors include age, clinical stage, tumour size, 
tumour circumscription, mitotic index and lym-
phovascular invasion (D’Angelo and Prat 2010; 
Abeler et al. 2009).
Leiomyosarcomas and undifferentiated uter-
ine sarcomas are highly aggressive neoplasms 
with a marked propensity for extrauterine spread 
and systemic metastasis; and nodal metastasis is 
not so common (McCluggage et al. 2014; Kapp 
et al. 2008).
In undifferentiated uterine sarcomas, a signifi-
cant proportion of patients (>60%) has advanced- 
stage disease at the time of diagnosis, with 
extrauterine spread of tumour to the upper abdo-
men, pelvic lymph nodes or even more distant 
sites such as the lungs (Leath et al. 2007).
On the other hand, low-grade endometrial 
stromal sarcomas have an indolent clinical course 
with good long-term survival, despite the ten-
dency for late recurrence. Stage is the most 
important prognostic factor, with FIGO stage I 
and II tumours having an excellent 5-year sur-
vival rate.
Adenosarcomas are mixed tumours of low 
malignant potential containing a benign epithe-
lial and a malignant stromal component, usually 
of low grade. They usually have a favourable 
prognosis with a 5-year survival rate above 80% 
unless associated with sarcomatous overgrowth 
or deep myometrial invasion (McCluggage et al. 
2014; Abeler et al. 2009).
The current standard of care for uterine sar-
comas remains surgery: total abdominal hyster-
ectomy with bilateral salpingo-oophorectomy. 
In younger patients preservation of the ovaries 
can be considered in early-stage disease.
For patients with evidence of extrauterine dis-
ease, surgical staging and cytoreduction are per-
formed only if intra-abdominal metastases are 
resectable and there is no extra-abdominal 
 disease. If patients are not surgical candidates, 
medical treatment should be offered. Whether 
systematic lymphadenectomy is needed is still 
controversial (Prat and Mbatani 2015).
Adjuvant chemotheraphy is decided in a case-
to-case base and not consensually indicated. 
Radiotherapy is also not routinely performed as it 
does not appear to provide a benefit in survival, 
but it may reduce local recurrence in high-risk 
women (Seddon and Davda 2011).
Recurrence can be treated either by surgical 
resection or by systemic chemotherapy, with hor-
monotherapy in particular cases, when hormonal 
receptors are present (Amant et al. 2009).
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